The statement confused experts who said that vaccines aimed at new pathogens have always been tested this way. "That has been ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results , but sales fell by 1.6% year on year to $15.53 ...

Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

HHS Secretary RFK Jr. tussled with Sen. Chris Murphy about measles vaccine safety. Who was right? Data shows that the two-dose measles vaccine is 97% effective at preventing measles and experts say ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 ... Management cited a pronounced decline in Gardasil sales in China, which offset growth in other segments, while ongoing ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...

HAPPY FRIDAY. IT’S GREAT TO SEE YOU. AS YOU KNOW, VACCINES HAVE BEEN A FREQUENT TARGET IN THE DEBATE ABOUT AUTISM. SO SO JUST TO JUST TO WE’LL BUILD A BASE. FIRST. TELL US AGAIN WHAT DOES WHAT ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen ...